Can you take Revuforj with Sibeprenlimab?
1 drug interaction and 12 additional warnings found for the following 2 drugs:
- Revuforj (revumenib)
- sibeprenlimab
Drug interactions
Moderate drug interactions
Moderate:
revumenib sibeprenlimab
Applies to: Revuforj (revumenib) and sibeprenlimab
Using revumenib together with sibeprenlimab may increase the risk of infections.
Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications.
Contact your doctor immediately if you develop signs or symptoms of infection such as fever, chills, feeling tired, cough, flu-like symptoms, aches and pains, and/or warm, red, or painful skin.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
revumenib Food/Lifestyle
Applies to: Revuforj (revumenib)
High fat content meals may affect the absorption of revumenib. It is recommended that revumenib be taken while fasting or with a low fat meal (approximately 400 calories, with 25% of calories from fat).
Grapefruit juice may also increase the blood levels of revumenib which can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening.
You may be more susceptible if you have:
- a heart condition called congenital long QT syndrome
- other cardiac diseases
- conduction abnormalities
- electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting)
Increased levels of revumenib may also increase the risk of developing a serious and potentially life-threatening condition called differentiation syndrome.
Symptoms of differentiation syndrome include:
- fever
- cough
- shortness of breath
- severe headache
- confusion
- dizziness
- rapid weight gain
- swelling
- decreased urination
You should seek immediate medical attention if you develop any of these symptoms and/or symptoms of QT prolongation such as sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with revumenib.
The risk and/or severity of other side effects may also increase, including nausea, vomiting, diarrhea, fever or infections. You may need additional monitoring if grapefruit or grapefruit juice are consumed during treatment with revumenib.
Talk to a healthcare provider if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
11 potential interactions Applies to: 9 conditions, including Heart Failure, Arrhythmia, Hypokalemia, Liver Disease, and Long QT Syndrome.
Arrhythmia
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Arrhythmia.
Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.
Heart Failure
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Heart Failure.
Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.
Hypokalemia
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Hypokalemia.
Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.
Immunodeficiency
Moderate:
sibeprenlimab
Sibeprenlimab has a moderate potential interaction with Immunodeficiency.
Sibeprenlimab suppresses the immune system, which may increase the risk of infections. Patients with chronic or recurring infections may have an increased risk of serious infection. Assess patients for active infections before and during treatment. If a serious infection develops, consider interrupting treatment until the infection is controlled.
Infection
Moderate:
sibeprenlimab
Sibeprenlimab has a moderate potential interaction with Infection.
Sibeprenlimab suppresses the immune system, which may increase the risk of infections. Patients with chronic or recurring infections may have an increased risk of serious infection. Assess patients for active infections before and during treatment. If a serious infection develops, consider interrupting treatment until the infection is controlled.
Liver Disease
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Liver Disease.
Revumenib has not been studied in patients with severe liver or renal impairment.
Moderate:
sibeprenlimab
Sibeprenlimab has a moderate potential interaction with Liver Disease.
Sibeprenlimab has not been studied in patients with liver dysfunction.
Long QT Syndrome
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Long QT Syndrome.
Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.
Magnesium Imbalance
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Magnesium Imbalance.
Revumenib can cause QTc interval prolongation. Correct electrolyte imbalances such as hypokalemia and hypomagnesemia, prior to treatment, and perform a baseline ECG. This drug should not be initiated in patients with QTcF greater than 450 msec. Monitor with ECG during treatment (once a week during the first 4 weeks and then monthly). More frequent ECG monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those taking other medications that can prolong the QTc interval.
Renal Dysfunction
Moderate:
Revuforj
The revumenib in Revuforj has a moderate potential interaction with Renal Dysfunction.
Revumenib has not been studied in patients with severe liver or renal impairment.
Moderate:
sibeprenlimab
Sibeprenlimab has a moderate potential interaction with Renal Dysfunction.
Sibeprenlimab has not been studied in patients with severe renal dysfunction.
Report options
More resources
Revuforj
A total of 583 drugs are known to interact with Revuforj.
- Revuforj is in the drug class miscellaneous antineoplastics.
- Revuforj is used to treat the following conditions:
sibeprenlimab
A total of 451 drugs are known to interact with sibeprenlimab.
- Sibeprenlimab is in the drug class miscellaneous uncategorized agents.
- Sibeprenlimab is used to treat Immunoglobulin A Nephropathy.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.